Table 2.
Clinicopathological characteristics for the entire cohort and subgroups according to AST/ALT ratio (AST/ALT ratio <1.23 are low group, otherwise high group) after propensity score matching
| Characteristics | Entire cohort | Low AST/ALT | High AST/ALT | P-value |
|---|---|---|---|---|
| Number of subjects | 602 | 301 | 301 | |
| Preoperative characteristics | ||||
| Age, years | 66.77±9.90 | 65.98±9.79 | 67.56±9.96 | 0.051 |
| Aged >65 years | 385 (64.0%) | 181 (60.1%) | 204 (67.8%) | 0.051 |
| Gender (male) | 285 (47.3%) | 147 (48.8%) | 138 (45.8%) | 0.463 |
| Body mass index | 24.58±3.52 | 24.67±3.34 | 24.49±3.69 | 0.516 |
| Diabetes | 99 (16.4%) | 51 (16.9%) | 48 (15.9%) | 0.742 |
| Hypertension | 224 (37.2%) | 114 (37.9%) | 110 (36.5) | 0.736 |
| Coronary disease | 67 (11.1%) | 29 (9.6%) | 38 (12.6%) | 0.243 |
| Alcohol | 6 5(10.8%) | 33 (11.0%) | 32 (10.6%) | 0.896 |
| Tobacco | 94 (15.6%) | 47 (15.6%) | 47 (15.6%) | 1.000 |
| Hydronephrosis | 296 (49.2%) | 142 (47.2%) | 154 (51.2%) | 0.328 |
| Tumor location (pelvis) | 310 (51.5%) | 151 (50.0%) | 159 (52.8%) | 0.514 |
| Tumor size (>5cm) | 88 (14.6%) | 40 (13.3%) | 48 (15.9%) | 0.356 |
| Postoperative characteristics | ||||
| Pathological T Stage | 0.492 | |||
| Ta | 6 (1.0%) | 1 (0.3%) | 5 (1.7%) | |
| T1 | 234 (38.9%) | 115 (38.2%) | 119 (39.5%) | |
| T2 | 196 (32.6%) | 97 (32.2%) | 99 (32.9%) | |
| T3 | 148 (24.6%) | 78 (25.9%) | 70 (23.3%) | |
| T4 | 18 (3.0%) | 10 (3.3%) | 8 (2.7%) | |
| Pathological N Stage | 0.120 | |||
| N0 | 561 (93.2%) | 280 (93.0%) | 281 (93.4%) | |
| N1 | 37 (6.1%) | 17 (5.6%) | 20 (6.6%) | |
| N2 | 4 (0.7%) | 4 (1.3%) | 0 (0.0%) | |
| Cellular grade | 0.653 | |||
| G1 | 15 (2.5%) | 8 (2.7%) | 7 (2.3%) | |
| G2 | 342 (56.8%) | 176 (58.5%) | 166 (55.1%) | |
| G3 | 245 (40.7%) | 117 (38.9%) | 128 (42.5%) | |
| Lymphatic microvascular invasion | 25 (4.15%) | 11 (44.0%) | 14 (56.0%) | 0.540 |
| Tumor major diameter | 3.39±2.26 | 3.33±2.38 | 3.56±2.33 | 0.542 |
| Tumor necrosis | 75 (12.5%) | 39 (13.0%) | 36 (12.0%) | 0.711 |
| Tumor hemorrhage | 19 (3.2%) | 8 (2.7%) | 11 (3.7%) | 0.484 |
| Tumor architecture (sessile) | 109 (18.1%) | 55 (18.3%) | 54 (17.9%) | 0.916 |
| Squamous metaplasia | 51 (8.5%) | 28 (9.3%) | 23 (7.6%) | 0.464 |
| Sarcomatoid differentiation | 26 (4.3%) | 13 (4.3%) | 13 (4.3%) | 1.000 |
| Glandular differentiation | 28 (4.7%) | 14 (4.7%) | 14 (4.7%) | 1.000 |